Wall Street analysts forecast that Medidata Solutions Inc (NASDAQ:MDSO) will report $189.93 million in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Medidata Solutions’ earnings, with the highest sales estimate coming in at $192.30 million and the lowest estimate coming in at $187.86 million. Medidata Solutions posted sales of $163.41 million during the same quarter last year, which would indicate a positive year over year growth rate of 16.2%. The firm is expected to report its next quarterly earnings results on Thursday, October 17th.

According to Zacks, analysts expect that Medidata Solutions will report full-year sales of $739.93 million for the current year, with estimates ranging from $737.50 million to $741.60 million. For the next financial year, analysts expect that the firm will report sales of $851.16 million, with estimates ranging from $835.64 million to $865.65 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Medidata Solutions.

Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings data on Monday, July 22nd. The company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.31. Medidata Solutions had a net margin of 6.43% and a return on equity of 8.64%. The firm had revenue of $180.50 million for the quarter, compared to analyst estimates of $179.95 million. During the same quarter in the prior year, the firm earned $0.43 EPS. The company’s revenue was up 15.8% on a year-over-year basis.

A number of research firms have issued reports on MDSO. Zacks Investment Research upgraded shares of Medidata Solutions from a “strong sell” rating to a “hold” rating and set a $78.00 target price on the stock in a research report on Tuesday, September 24th. BidaskClub upgraded shares of Medidata Solutions from a “sell” rating to a “hold” rating in a research report on Tuesday, October 1st. SunTrust Banks upped their target price on shares of Medidata Solutions from $85.00 to $92.25 and gave the company a “hold” rating in a research report on Thursday, June 13th. ValuEngine downgraded shares of Medidata Solutions from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Medidata Solutions from an “underweight” rating to a “neutral” rating in a research report on Wednesday, June 12th. Eleven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Medidata Solutions presently has an average rating of “Hold” and a consensus target price of $83.71.

Medidata Solutions stock traded down $0.02 during trading hours on Friday, reaching $91.62. 36,331 shares of the company’s stock traded hands, compared to its average volume of 797,390. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.56 and a current ratio of 2.56. Medidata Solutions has a fifty-two week low of $60.10 and a fifty-two week high of $98.60. The firm has a market capitalization of $5.72 billion, a price-to-earnings ratio of 95.46, a PEG ratio of 6.91 and a beta of 1.22. The firm’s 50 day moving average is $91.60 and its 200-day moving average is $88.74.

Several large investors have recently made changes to their positions in MDSO. Municipal Employees Retirement System of Michigan raised its holdings in Medidata Solutions by 1.1% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 11,510 shares of the company’s stock worth $1,042,000 after buying an additional 120 shares during the period. United Capital Financial Advisers LLC raised its holdings in Medidata Solutions by 0.4% during the 2nd quarter. United Capital Financial Advisers LLC now owns 41,107 shares of the company’s stock worth $3,721,000 after buying an additional 171 shares during the period. Flagship Harbor Advisors LLC raised its holdings in Medidata Solutions by 58.3% during the 2nd quarter. Flagship Harbor Advisors LLC now owns 475 shares of the company’s stock worth $42,000 after buying an additional 175 shares during the period. Zions Bancorporation N.A. grew its stake in shares of Medidata Solutions by 5.9% during the 2nd quarter. Zions Bancorporation N.A. now owns 3,521 shares of the company’s stock worth $319,000 after acquiring an additional 195 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Medidata Solutions by 0.8% during the 2nd quarter. Russell Investments Group Ltd. now owns 51,056 shares of the company’s stock worth $4,621,000 after acquiring an additional 402 shares in the last quarter. Institutional investors and hedge funds own 91.31% of the company’s stock.

About Medidata Solutions

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.

Featured Story: How does inflation affect different investments?

Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.